Cobaias como modelo para teste de vacinas inativadas contra o herpesvírus bovino tipo 1 e o vírus da diarréia viral bovina

Silva, Letícia Frizzo da; Diel, Diego G.; Cilento, Maria do Carmo; Weiblen, Rudi; Flores, Eduardo Furtado

doi:10.1590/s0103-84782007000400023

Cited by 4 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These two vaccines stimulated the production of neutralizing antibodies only in some animals and their titers (5) were lowest for tested bovine pestiviruses (Table 1). The performance of these vaccines was similar to that observed in other studies as well, in which, higher levels of immune responses against the bovine alphaherpesvirus were detected compared to those of the bovine pestiviruses (ANZILIERO et al, 2015;SILVA et al, 2007a;VOGEL et al, 2002aVOGEL et al, , 2002b.…”

Section: Discussionsupporting

confidence: 86%

“…The methodology of vaccine production against BoHV-1, BoHV-5 and bovine pestiviruses is not standardized and allows the preparation of immunogens using variable composition of strains and adjuvants (SILVA, et al, 2007a;ANZILIERO et al, 2015). Differences in the immunogenicities of commercial vaccines have already been demonstrated upon their evaluation and, in some cases, also induced inadequate immune responses (ANZILIERO et al, 2015;FULTON & BURGE, 2000;VOGEL et al, 2002aVOGEL et al, , 2002b.…”

Section: Microbiologymentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity in sheep of Uruguayan commercial vaccines against bovine alphaherpesvirus 1, 5 and bovine pestiviruses

et al. 2020

View full text Add to dashboard Cite

The serological responses induced by four commercial inactivated Uruguayan vaccines against bovine alphaherpesviruses (BoHV)-1 and -5 and bovine pestiviruses (BVDV-1, BVDV-2, and HoBiPeV) were evaluated in sheep. Thirty-seven sheep were immunized twice (day 0 and 25) and their serum samples were tested at different intervals (days 0, 25, 40, 60, and 90) post-vaccination (PV). Among the four vaccines tested, only one (G4) could induce the production of moderate neutralizing antibody titers against BoHV-1 and -5 and BVDV-1 and -2. The G3 vaccine showed a neutralizing serological response against the bovine alphaherpesviruses only. The G1 and G2 vaccines produced extremely low levels of antibodies in a few vaccinated animals only (geometric mean titers (GMT) 2.2). Similar levels of immunological responses were induced by the G4 vaccine against BoHV-1 and -5, and titers of neutralizing antibodies induced in approximately 70% of the animals are known to confer protection (GMT > 8). For bovine pestiviruses, the vaccine stimulated response of G4 against BVDV-2 was higher compared to that against BVDV-1, and extremely low for HoBiPeV. The peak of neutralizing antibodies to BoHV-1 and BVDV-1 was observed on days 40 and 60 PV, respectively. Thereafter, a remarkably decrease in neutralizing antibody response was observed at day 90 PV. These results demonstrated that tested commercial Uruguayan vaccines did not induce a serological response of adequate magnitude and duration. Thus, it is important to periodically review formulations and compositions of commercial vaccines against bovine alphaherpesviruses and pestiviruses.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Microbiologymentioning

confidence: 99%

Immunogenicity in sheep of Uruguayan commercial vaccines against bovine alphaherpesvirus 1, 5 and bovine pestiviruses

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Given this, reproductive vaccines represent an essential strategy for the control of infections caused by both BVDV and BoHV-1, in an attempt to limit losses related to lower conception rates, early embryonic death, abortions, stillbirths and birth of premature calves caused by viral infections (Walz et al 2017). Vaccination of cattle against BVDV and BoHV-1 is not yet a widespread practice in our country (Silva et al 2007b), but a large number of commercial vaccines licensed against these agents in Brazil shows a trend towards continuous use vaccination protocols associated with reproduction. In Brazil, there are around 20 commercial reproductive vaccines, most of them composed of inactivated strains of BVDV (Brasil 2019).…”

Section: Introductionmentioning

confidence: 99%

“…The predominant response profile in this vaccine is the B-lymphocyte-mediated Th2 (humoral) type, which is critical for the production of antibodies that neutralize infectious viral particles before they infect host target cells. Despite these advantages, the search for vaccines that are also capable of stimulating cellular response (Th1) is essential, as this is the primary mechanism for host defense after the establishment of infection caused by viral agents (Kelling 2004, Silva et al 2007b, Platt et al 2008, Kreutz 2012. Given this context, this type of vaccine requires the addition of adjuvants in order to increase immunogenicity, improving antigen presentation, and thus amplifying both humoral and cellular immune response.…”

mentioning

confidence: 99%

Serological response against bovine herpesvirus and bovine viral diarrhea virus induced by commercial vaccines in Holstein heifers

et al. 2019

View full text Add to dashboard Cite

Vaccination is a strategy to the prevention and control of reproductive diseases caused by bovine viral diarrhea virus (BVDV) and bovine herpesvirus type 1 (BoHV-1), however the various compositions of commercial vaccines should be evaluated for their ability to induce protection mediated by antibodies. The objective of this research was to evaluate the production of specific neutralizing Abs against BVDV-1 and 2, and BoHV-1 induced by commercial vaccines composed by different adjuvants. Holstein heifers were vaccinated and distributed in three experimental groups: Group I (G1) was vaccinated with a commercial vaccine containing inactivated BVDV-1, BVDV-2 and BoHV-1 diluted in alum hydroxide as adjuvant (n=9); Group II (G2) was vaccinated with an product containing inactivated strains of BVDV-1, BVDV-2, BoHV-1 and BoHV-5 diluted in oil emulsion as adjuvant (n=10); Group III (G3) was vaccinated with a commercial vaccine containing inactivated BVDV-1 and BVDV-2, besides live modified thermosensitive BoHV-1, diluted in Quil A, amphigen and cholesterol (n=10); A control, non-vaccinated group (n=6) was mock vaccinated with saline. Heifers received two subcutaneous doses of 5mL of each commercial vaccine on the right side of the neck, with 21 days interval. Humoral immune response was assessed by the virus neutralization test (VN) against BVDV-1 (NADL and Singer strains), BVDV-2 (SV253 strain) and BoHV-1 (Los Angeles strain) in serum samples collected on vaccination days zero (D0), 21 (D21) and 42 (D42; 21 days after boosting). Neutralizing Abs against BVDV-1 NADL was detected only in D42, regardless of the vaccine used. Similar geometric mean titers (GMT) for BVDV-1 NADL were observed between G1 (log2=5.1) and G3 (log2=5.1). The seroconversion rate (%) was higher in G1 (78%) when compared to G2 (10%) and G3 (40%). For BVDV-1 Singer, it was also possible to detect Abs production in G1 (log2=5.8, 100% seroconversion rate) and G3 (log2=3.5, seroconversion rate = 60%), only after the booster dose (D42). Neutralizing Abs to BVDV-2 (SV253) were detected only in G3, observing 90% seroconversion associated with high titers of Abs (log2=6.7) after the 2nd dose of vaccine (D42). Heifers from G1 and G3 responded to BoHV-1 after the first dose (D21): G1 (log2=2.5, seroconversion rate = 67%) and G3 (log2=0.7, seroconversion rate = 80%). In D42, a higher magnitude response was observed in the heifers from G3 (log2=6.1, 100%) compared with G1 (log2=4.3, 100%) and G2 (log2=2.7, 60%). Based on the data obtained, it can be concluded that the commercial vaccine contained aluminum hydroxide (G1) was most effective in the induction of antibodies against BVDV-1. On the other hand, this vaccine did not induce the production of neutralizing Abs against BVDV-2. Only the heifers from G3 (Quil A, amphigen and cholesterol) generated neutralizing Abs against BVDV-2. The animals that received commercial vaccine containing oil emulsion as adjuvant (G2) had a weak/undetectable response against BVDV-1 and BVDV-2. The best protective response against BoHV-1 was observed in heifers vaccinated with the live modified thermosensitive virus.

show abstract

“…Teoricamente, os vírus presentes nas vacinas inativadas atuam como microrganismos extracelulares que induzem resposta imune predominantemente humoral (Th2), mediada pelos linfócitos B, no entanto apenas duas vacas VAC apresentavam ACs específicos para o BVDV. Assim, recomenda-se a busca por estratégias para amplificar as respostas imunes induzidas pelas vacinas comerciais contra o vírus da BVD, pois, apesar da diversidade de imunógenos disponíveis, ainda não existe uma vacina totalmente efetiva para o controle dessas enfermidades (Silva et al, 2007).…”

Section: Resultsunclassified

Influência da vacinação materna na transferência de imunidade passiva contra as viroses respiratórias dos bovinos

Baccili

Silva

Baldacim

et al. 2018

Arq. Bras. Med. Vet. Zootec.

View full text Add to dashboard Cite

RESUMOO objetivo deste estudo longitudinal foi avaliar a influência da vacinação materna na transferência de anticorpos (ACs) contra as viroses respiratórias em bezerros. Para tanto, vacas e bezerros foram distribuídos em dois grupos conforme a realização (VAC, n=6) ou não (NVAC, n=4) da vacinação no pré-parto. Amostras sanguíneas foram obtidas após a parição (D0); em seguida, apenas os bezerros foram acompanhados até D180. ACs séricos foram determinados pela vírus-neutralização (VN) contra BVDV, BoHV-1, BRSV e BPI3-V. Vacas VAC apresentaram diferenças para ACs contra BoHV-1 (P=0,01) em D0. As frequências (%) de bezerros soropositivos para BoHV-1 foram maiores em VAC do D2 ao D120; para BRSV em D4, D8, D10 e D150 (P≤0,08); medianas de ACs contra BoHV-1 em VAC do D2 ao D120 (P=0,08). A vacinação das vacas no pré-parto foi fundamental para a transferência e a duração de ACs contra BoHV-1 e BRSV, porém o protocolo adotado não foi eficiente para o aumento de ACs para BVDV e BPI3-V. A eficácia parcial da vacinação materna não inviabiliza a sua recomendação devido à importância do Herpesvírus e do BRSV na DRB, porém estratégias para a melhoria nas respostas imunes contra as demais viroses devem ser estabelecidas. to BRSV D4, D8, D10 and D150 (P≤0.08); higher medians of Abs against Palavras-chave: bovino, colostro, anticorpos maternos ABSTRACT

show abstract

Cobaias como modelo para teste de vacinas inativadas contra o herpesvírus bovino tipo 1 e o vírus da diarréia viral bovina

Cited by 4 publications

References 19 publications

Immunogenicity in sheep of Uruguayan commercial vaccines against bovine alphaherpesvirus 1, 5 and bovine pestiviruses

Immunogenicity in sheep of Uruguayan commercial vaccines against bovine alphaherpesvirus 1, 5 and bovine pestiviruses

Serological response against bovine herpesvirus and bovine viral diarrhea virus induced by commercial vaccines in Holstein heifers

Influência da vacinação materna na transferência de imunidade passiva contra as viroses respiratórias dos bovinos

Contact Info

Product

Resources

About